Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty

Vaccine

Volumn 33, Issue 36, 2015, Pages 4565-4571

  DiazGranados, Carlos A ^a   Dunning, Andrew J ^a   Robertson, Corwin A ^a   Talbot, H Keipp ^b   Landolfi, Victoria ^a   Greenberg, David P ^a,c  

^a SANOFI PASTEUR   (France)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Aged; Aged, 80 and over; Clinical trial, phase III; Influenza vaccines, human; Vaccines, inactivated

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; BIOLOGICAL MARKER; INACTIVATED VACCINE; VIRUS ANTIBODY;

AGE; AGED; ANTIBODY TITER; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; FRAIL ELDERLY; HUMAN; IMMUNOGENICITY; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARD; BLOOD; CLINICAL TRIAL; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA, HUMAN; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; BIOMARKERS; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; TREATMENT OUTCOME; VACCINES, INACTIVATED;

EID: 84939569382     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.003     Document Type: Article

References (22)

1. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292(11):1333-1340.
2. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59(RR-8):1-62.
3. Simonsen L., Reichert T.A., Viboud C., Blackwelder W.C., Taylor R.J., Miller M.A. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005, 165:265-272.
4. Falsey A., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009, 200:172-180.
5. DiazGranados C.A., Dunning A.J., Kimmel M., Kirby D., Treanor J., Collins A., et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014, 371(7):635-645.
6. Kendal A.P., Pereira M.S., Skehel J.J. Hemagglutination inhibition. Concepts and Procedures for Laboratory-Based Influenza Surveillance 1982, B17-B35. Centers for Disease Control and Prevention and Pan-American Health Organization, Atlanta, GA. A.P. Kendal, M.S. Pereira, J.J. Skehel (Eds.).
7. Mitnitski A.B., Graham J.E., Mogilner A.J., Rockwood K. Frailty, fitness and late-life mortality in relation to chronological and biological age. BMC Geriatr 2002, 2:1.
8. Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998, 17:857-872.
9. Breslow N.E. Statistics in epidemiology: the case-control study. J Am Stat Assoc 1996, 91(433):14-28.
10. Palache A. Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential influence of national public health policies. Vaccine 2011, 29:9459-9466.
11. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., Levandowski R.A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995, 123:518-527.
12. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994, 272(21):1661-1665.
13. Praditsuwan R., Assantachai P., Wasi C., Puthavatana P., Kositanont U. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J Med Assoc Thai 2005, 88(2):256-264.
14. McElhaney J.E. Influenza vaccine responses in older adults. Ageing Res. Rev. 2011, 10(3):379-388.
15. Trzonkowski P., Myśliwska J., Pawelec G., Myśliwski A. From bench to bedside and back: the SENIEUR Protocol and the efficacy of influenza vaccination in the elderly. Biogerontology 2009, 10(1):83-94.
16. Rockwood K., Fox R.A., Stolee P., Robertson D., Beattie B.L. Frailty in elderly people an evolving concept. CMAJ 1994, 150:489-495.
17. Izurieta H.S., Thadani N., Shay D.K., Lu Y., Maurer A., Foppa I.M., et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 2015, 15(3):293-300.
18. Barker W.H., Mullooly J.P. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch. Intern. Med. 1982, 142(1):85-89.
19. Herrera G.A., Iwane M.K., Cortese M., Brown C., Gershman K., Shupe A., et al. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado. United States, 2003-2004. Vaccine 2007, 25:154-160.
20. Blumberg E.A., Albano C., Pruett T., Isaacs R., Fitzpatrick J., Bergin J., et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996, 22:295-302.
21. Dorrell L., Hassan I., Marshall S., Chakraverty P., Ong E. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS 1997, 8:776-779.
22. Yao X., Hamilton R.G., Weng N.P., Xue Q.L., Bream J.H., Li H., et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine 2011, 29(31):5015-5021.